Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2025; 14(01): 045-052
DOI: 10.1055/s-0044-1791768
Original Article
Breast Cancer

Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2−ve Early Breast Cancer (EBC)

Purvish M. Parikh
1   Department of Clinical Hematology, Sri Ram Cancer Center, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan, India
,
Amish Vora
2   Department of Medical Oncology, Hope Oncology Center, New Delhi, India
,
Rajan Yadav
3   Department of Medical Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
,
Akhil Kapoor 
4   Department of Medical Oncology, Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, Uttar Pradesh, India
,
Tarini Sahoo
5   Department of Medical Oncology, Silverline Hospital, Bhopal, Madhya Pradesh, India
,
Senthil Rajappa
6   Department of Medical Oncology, Basavatarakam Indo American Cancer Hospital, Hyderabad, Telangana, India
,
Govind Babu Kanakashetty 
7   Department of Medical Oncology, St. John's Medical College and Hospital, Bengaluru, Karnataka, India
,
M. Vamshi Krishna
8   Department of Medical Oncology, AIG Hospital, Hyderabad, Telangana, India
,
Ghanashyam Biswas
9   Department of Medical Oncology, Sparsh Hospitals and Critical Care Pvt Ltd., Bhubaneswar, Orissa, India
,
Ankur Bahl
10   Department of Medical Oncology, Fortis Medical, Gurugram, Haryana, India
,
Nikhil Ghadyalpatil
11   Department of Medical Oncology, Yashoda Hospital, Hyderabad, Telangana, India
,
Thirumalairaj Raja
12   Department of Medical Oncology, Apollo Hospital, Chennai, Tamil Nadu, India
,
Jyoti Bajpai
13   Department of Medical Oncology, Apollo Hospital, Navi Mumbai, Maharashtra, India
,
Amol Akhade
14   Department of Medical Oncology, Bethany Hospital, Thane, Maharashtra, India
,
Randeep Singh
15   Department of Medical Oncology, Narayana Health, Gurugram, Haryana, India
,
Shyam Aggarwal
16   Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India
,
Maheboob Basade
17   Department of Medical Oncology, Saifee Hospital, Mumbai, Maharashtra, India
,
S.H. Advani
18   Department of Medical Oncology, Sushrusha Hospital, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

It is still not possible for all patients with early breast cancer to be cured. Even when they respond well to initial therapy, there exists a substantial risk for recurrence, sometimes after several years. With the availability of cyclin-dependent kinase (CDK) 4/6 inhibitors the role of adjuvant therapy has improved, and so has the chance of cure. These consensus guidelines will ensure that the community oncologist will be able to take the right decision for their patient. The expert committee shares their real-world experience as well as the consensus voting results. Patients eligible for adjuvant therapy with CDK4/6 inhibitors should start that treatment at the earliest. Based on current published data, abemaciclib is the preferred CDK4/6 inhibitor that should be used in eligible patients (unless contraindicated). To ensure optimal dose intensity and adherence to treatment schedule, use of literature and patient information material can improves compliance. Treatment modification requires early reporting of adverse effects, a responsibility of the patient and caregiver (relatives).

Keywords

targeted therapy - IDFS - high risk - regulatory approval


Publication History

Received: 13 September 2024

Accepted: 14 September 2024

Article published online:
18 November 2024

© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parikh PM, Bhattacharyya GS, Biswas G. et al. Practical consensus recommendations for optimizing risk versus benefit of chemotherapy in patients with HR positive Her2 negative early breast cancer in India. South Asian J Cancer 2021; 10 (04) 213-219
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386 (10001): 1341-1352
    CrossrefPubMedSearch in Google Scholar
  • 3 Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 2020; 395 (10226): 817-827
    CrossrefPubMedSearch in Google Scholar
  • 4 Ding L, Cao J, Lin W. et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 2020; 21 (06) 1960
    CrossrefPubMedSearch in Google Scholar
  • 5 Roskoski Jr R. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacol Res 2019; 139: 471-488
    CrossrefPubMedSearch in Google Scholar
  • 6 Cicenas J, Simkus J. CDK inhibitors and FDA: approved and orphan. Cancers (Basel) 2024; 16 (08) 1555
    CrossrefPubMedSearch in Google Scholar
  • 7 Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - author's reply. Lancet Oncol 2023; 24 (09) e357
    CrossrefPubMedSearch in Google Scholar
  • 8 Johnston SRD, Toi M, O'Shaughnessy J. et al; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24 (01) 77-90
    CrossrefPubMedSearch in Google Scholar
  • 9 Slamon DJ, Stroyakovskiy D, Yardley DA. et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: primary results from the phase III NATALEE trial. J Clin Oncol 2023; 41: LBA500
    CrossrefSearch in Google Scholar
  • 10 Aggarwal S, Vaid A, Ramesh A. et al. Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling. South Asian J Cancer 2018; 7 (02) 96-101
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Parikh P, Babu G, Singh R. et al. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method. BMC Cancer 2023; 23 (01) 714
    CrossrefPubMedSearch in Google Scholar
  • 12 Parikh PM, Hingmire SS, Bhavesh P. et al. Oncology Gold Standard™ consensus statement on counselling patients for molecular testing and personalized cancer care. Int J Mol Immuno Oncol 2017; 2: 47-57
    CrossrefSearch in Google Scholar
  • 13 Parikh PM, Aggarwal S, Biswas G. et al. Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. South Asian J Cancer 2023; 12 (02) 93-99
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health 2020; 8: 457
    CrossrefPubMedSearch in Google Scholar
  • 15 Agostinetto E, Arecco L, de Azambuja E. Adjuvant CDK4/6 inhibitors for early breast cancer: how to choose wisely?. Oncol Ther 2024; 12 (01) 19-29
    CrossrefPubMedSearch in Google Scholar
  • 16 Johnston SRD, Harbeck N, Hegg R. et al; monarchE Committee Members and Investigators. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 2020; 38 (34) 3987-3998
    CrossrefPubMedSearch in Google Scholar
  • 17 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 2024; 390 (12) 1080-1091
    CrossrefPubMedSearch in Google Scholar
  • 18 Johnston SRD, Toi M, O'Shaughnessy J. et al; monarchE Committee Members. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24 (01) 77-90
    CrossrefPubMedSearch in Google Scholar
  • 19 Slamon DJ, Fasching PA, Hurvitz S. et al. Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 2023 ;15:17588359231178125 Erratum in: Ther Adv Med Oncol. 2023 Sep 29;15:17588359231201818. doi: 10.1177/17588359231201818. PMID: 37275963; PMCID: PMC10233570
    Search in Google Scholar
  • 20 Rastogi P, O'Shaughnessy J, Martin M. et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 2024; 42 (09) 987-993 Erratum in: J Clin Oncol. 2024 Jun 10;42(17):2111. doi: 10.1200/JCO.24.00711. PMID: 38194616; PMCID: PMC10950161
    CrossrefPubMedSearch in Google Scholar
  • 21 Paluch-Shimon S, Neven P, Huober J. et al. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023 ;15:17588359231151840
    Search in Google Scholar
  • 22 Fasching PA, Hack CC, Nabieva N. et al. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole. Eur J Cancer 2024; 209: 114239
    CrossrefPubMedSearch in Google Scholar
  • 23 Martin M, Hegg R, Kim SB. et al. Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial. JAMA Oncol 2022; 8 (08) 1190-1194
    CrossrefPubMedSearch in Google Scholar
  • 24 Toi M, Boyle F, Im YH. et al. Adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarchE cohort 1. Oncologist 2023; 28 (01) e77-e81
    CrossrefPubMedSearch in Google Scholar
  • 25 Harbeck N, Rastogi P, Martin M. et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32 (12) 1571-1581
    CrossrefPubMedSearch in Google Scholar
  • 26 Rugo HS, O'Shaughnessy J, Boyle F. et al; monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol 2022; 33 (06) 616-627
    CrossrefPubMedSearch in Google Scholar
  • 27 Yousuf M, Alam M, Shamsi A. et al. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: a review on therapeutic implications. Int J Biol Macromol 2022; 218: 394-408
    CrossrefPubMedSearch in Google Scholar
  • 28 Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. CDK4/6 inhibitors: the mechanism of action may not be as simple as once thought. Cancer Cell 2018; 34 (01) 9-20
    CrossrefPubMedSearch in Google Scholar
  • 29 Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Ther Adv Med Oncol 2023;15:17588359231205848
  • 30 Grinshpun A, Tarantino P. The Evolving Role of CDK4/6 Inhibitors in the Treatment of Advanced and Early-Stage Breast Cancer: Lessons Learned From SONIA and NATALEE. Accessed August 27, 2024 at: https://dailynews.ascopubs.org/do/evolving-role-cdk4-6-inhibitors-treatment-advanced-and-early-stage-breast-cancerst
  • 31 Haslam A, Ranganathan S, Prasad V, Olivier T. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer 2024; 207: 114192
    CrossrefPubMedSearch in Google Scholar
  • 32 Ergun Y, Dogan M, Ucar G, Karacin P, Karacin C. Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis. Expert Opin Pharmacother 2023; 24 (17) 1901-1909
    CrossrefPubMedSearch in Google Scholar
  • 33 Tolaney SM, Guarneri V, Seo JH. et al. Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer 2024; 199: 113555
    CrossrefPubMedSearch in Google Scholar
  • 34 Goetz MP, Cicin I, Testa L. et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer 2024; 10 (01) 34
    CrossrefPubMedSearch in Google Scholar
  • 35 Schäffler H, Mergel F, Pfister K. et al. The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German breast cancer centers. Int J Mol Sci 2023; 24 (22) 16366
    CrossrefPubMedSearch in Google Scholar
  • 36 Wani K, Patel K, Dabak V. Hepatotoxicity after CDK 4/6 inhibitor initiation in the treatment of hormone-positive metastatic breast cancer. Cureus 2023; 15 (06) e40871
    PubMedSearch in Google Scholar
  • 37 Korde LA, Somerfield MR, Carey LA. et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 2021; 39 (13) 1485-1505
    CrossrefPubMedSearch in Google Scholar
  • 38 Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH. Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer Guideline Expert Panel. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer-cyclin-dependent kinase 4 and 6 inhibitors: ASCO guideline rapid recommendation update. J Clin Oncol 2024; 42 (18) 2233-2235
    CrossrefPubMedSearch in Google Scholar
  • 39 Leo CP, Hentschel B, Szucs TD, Leo C. FDA and EMA approvals of new breast cancer drugs-a comparative regulatory analysis. Cancers (Basel) 2020; 12 (02) 437
    CrossrefPubMedSearch in Google Scholar
  • 40 Parikh PM, Sahoo TP, Biswas G. et al. practical consensus guidelines for the use of S-1 in GI malignancies. South Asian J Cancer 2024; 13 (01) 77-82
    Thieme ConnectPubMedSearch in Google Scholar
  • 41 Wander SA, Han HS, Zangardi ML. et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw 2021; •••: 1-8
    CrossrefPubMedSearch in Google Scholar
  • 42 Kalinsky K, Accordino MK, Chiuzan C. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol 2023; 41 (24) 4004-4013
    CrossrefPubMedSearch in Google Scholar
  • 43 Gnant M, Dueck AC, Frantal S. et al; PALLAS groups and investigators. Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14–03). J Clin Oncol 2022; 40 (03) 282-293
    CrossrefPubMedSearch in Google Scholar
  • 44 Loibl S, Marmé F, Martin M. et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer—the penelope-B trial. J Clin Oncol 2021; 39 (14) 1518-1530
    CrossrefPubMedSearch in Google Scholar
  • 45 Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist 2017; 22 (09) 1039-1048
    CrossrefPubMedSearch in Google Scholar
  • 46 Accessed August 27, 2024 at: https://clinicaltrials.gov/study/NCT04565054
  • 47 Accessed August 27, 2024 at: https://clinicaltrials.gov/study/NCT04584853